Since the beginning of the COVID-19 pandemic caused by SARS-CoV-2, millions of patients
have been diagnosed and many of them have died from the disease worldwide. The
identification of novel therapeutic targets are of utmost significance for prevention
and treatment of COVID-19. SARS-CoV-2 is a single-stranded RNA virus with a 30 kb genome
packaged into a membrane-enveloped virion, transcribing several tens of proteins. The
belief that the amino acid sequence of proteins determines their 3D structure which, in
turn, determines their function has been a central principle of molecular biology for a
long time. Recently, it has been increasingly realized, however, that there is a large
group of proteins that lack a fixed or ordered 3D structure, yet they exhibit important
biological activities—so-called intrinsically disordered proteins and protein
regions (IDPs/IDRs). Disordered regions in viral proteins are generally associated with
viral infectivity and pathogenicity because they endow the viral proteins the ability to
easily and promiscuously bind to host proteins; therefore, the proteome of SARS-CoV-2
has been thoroughly examined for intrinsic disorder. It has been recognized that, in
fact, the SARS-CoV-2 proteome exhibits significant levels of structural order, with only
the nucleocapsid (N) structural protein and two of the nonstructural proteins being
highly disordered. The spike (S) protein of SARS-CoV-2 exhibits significant levels of
structural order, yet its predicted percentage of intrinsic disorder is still higher
than that of the spike protein of SARS-CoV. Noteworthy, however, even though IDPs/IDRs
are not common in the SARS-CoV-2 proteome, the existing ones play major roles in the
functioning and virulence of the virus and are thus promising drug targets for rational
antiviral drug design. Presented here is a COVID-19 perspective on the intrinsically
disordered proteins, summarizing recent results on the SARS-CoV-2 proteome disorder
features, their physiological and pathological relevance, and their prominence as
prospective drug target sites.